ISIlaria Sauzullo

Ilaria Sauzullo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ilaria Sauzullo has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Claudio Maria Mastroianni

    Department of Public Health and Infectious Diseases Sapienza University of Rome Rome Italy

    23 shared publications
  • Vincenzo Vullo

    Department of Public Health and Infectious Diseases, 'Sapienza' University, Piazzale Aldo Moro 1, 00185, Rome, Italy

    18 shared publications
  • Fabio Mengoni

    Department of Public Health and Infectious Diseases, 'Sapienza' University, Piazzale Aldo Moro 1, 00185, Rome, Italy

    17 shared publications
  • Miriam Lichtner

    Department of Public Health and Infectious Diseases, 'Sapienza' University, Piazzale Aldo Moro 1, 00185, Rome, Italy

    10 shared publications
  • Raffaella Rossi

    Department of Public Health and Infectious Diseases, Sapienza University, Piazzale Aldo Moro 1, 00185, Rome, Italy

    8 shared publications
  • Anna Paola Massetti

    Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy

    7 shared publications

Latest Publications

  • Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis

    by Ilaria Sauzullo, Fabio Mengoni, Claudia Mascia, Paolo Pavone, Giulia Savelloni, Anna Paola Massetti, Miriam Lichtner, Vincenzo Vullo, Claudio M. Mastroianni

    The new QuantiFERON-TB Gold Plus employs modified peptides optimized to elicit an IFNγ response from CD8+ cytotoxic T lymphocytes in addition to CD4+ T cells. With a view to improve the difficult identification of TB cases, we assessed the combination of two specific immunological markers comprising IFNγ secretion and T cells co-expression of CD25 and CD134 in response to Mycobacterium tuberculosis-specific antigens. A total of 34 subjects with suspected TB and 10 age-matched HD were prospectively enrolled. Assessing the performance of QFT-Plus in terms of the TB1 and TB2 results, we found that in TB patients, the quantitative IFNγ value in TB2 was similar to that in TB1, and we did not find any differences irrespective of the disease (pulmonary or extra-pulmonary). The flow cytometric CD25/CD134 assay, allowed a more accurate differentiation between M. tuberculosis-infected and uninfected patients, with a better combination of sensitivity and specificity, especially by evaluation of CD4+ T-cell subset. All individuals with negative QFT-Plus results displayed a positive CD25/CD134 response. Overall, a positive correlation was found between T cells co-expressing CD25/CD134 and IFNγ levels in response to both QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes. We demonstrated that both TB1 and TB2 induce a higher expression of CD25+CD134+ markers on CD4+ T cells among infected TB subjects, compared to the lower degree of CD8+ T cells, mainly induced to TB2 stimulation. We suggest that a combined use of classic QFT-Plus and specific CD25/CD134 response may be a useful means in the diagnostic workup for active TB.


  • Open Access

    Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases

    by Ilaria Sauzullo, Rossana Scrivo, Paola Sessa, Fabio Mengoni, Vincenzo Vullo, Guido Valesini, Claudio Maria Mastroianni

    The aim of the study was to clarify the effect of long-term anti-TNF therapy on T cell function in patients with rheumatologic immune-mediated inflammatory diseases (IMID). The production of IFNγ by T cells was evaluated at baseline and after 1, 2, 4, and 8 years of anti-TNF agents by means of a QuantiFERON-TB Gold In-Tube assay. The T cell proliferation and surface co-expression of CD25/CD134 in response to phytohaemagglutinin together with the in vitro impact of anti-TNF therapy on the functional capacity of T cells were evaluated after 8 years from the onset of the biological treatment. Age-matched healthy donors were enrolled as controls. The quantitative mitogen-induced IFNγ responses significantly increased with respect to baseline at each time point, apart from the determination after 4 years. We found an increased expression of CD25/CD134 in CD4+ compared to CD8+ T cells both in patients and controls. The in vitro addition of anti-TNF agents induced a significant decrease of both the IFNγ response and of CD25/CD134, whereas no effect on the intensity of the proliferative response was observed. Our data provide a biological basis for the reassuring issues on the safety of long-term anti-TNF treatment in patients with IMID.


    • 23 August 2016
      • Vol. 39  (4) , 304-306

    Diagnostic accuracy of Xpert MTB/RIF versus smear microscopy in the early diagnosis tuberculosis in the real life of "Umberto I" Hospital Rome.

    by Ilaria Sauzullo, Donatella Maria Rodio, Samantha Facchinetti, Gianluca Puggioni, Massimiliano De Angelis, Paola Goldoni, Vincenzo Vullo, Fabio Mengoni, Maria Trancassini, Valeria Pietropaolo

    Early diagnosis of tuberculosis (TB) is one of the primary challenges in curtailing the spread of TB. This study aimed to determine the diagnostic accuracy of Xpert MTB/RIF for the identification of M. tuberculosis in clinical specimens, and compare this to a microscopist's diagnostic performance. Xpert MTB/ RIF was positive in all specimens with culture-confirmed TB, giving a higher sensitivity than the smear microscopy (100% versus 63%). The use of the Xpert MTB/RIF, as part of routine assay, permits rapid diagnosis of TB and enables clinicians to start an effective treatment.


  • Open Access

    Multifunctional Analysis of CD4+T-Cell Response as Immune-Based Model for Tuberculosis Detection

    by Miriam Lichtner, Claudia Mascia, Ilaria Sauzullo, Fabio Mengoni, Serena Vita, Raffaella Marocco, Valeria Belvisi, Gianluca Russo, Vincenzo Vullo, Claudio M. Mastroianni

    Mono- and multifunctional specific CD4+and CD8+T-cell responses were evaluated to improve the immune-based detection of active tuberculosis (TB) and latent infection (LTBI). We applied flow cytometry to investigate cytokines profile (IFN-γ, TNF-α, and IL-2) of T cells after stimulation with TB antigens in 28 TB-infected subjects (18 active TB and 10 LTBI) and 10 uninfected controls. Cytokines production by CD4+T cells at single-cell levels was higher in TB-infected subjects than uninfected controlsP<0.0001. Assigning to activated CD4+T cells, producing any of the three cytokines, a cut-off >0.45%, it was possible to differentiate TB-infected (>0.45%) by uninfected subjects (<0.45%). Among TB-infected subjects, the frequencies of multifunctional CD4+T cells, simultaneously producing all 3 cytokines, are lower in active TB than LTBI subjectsP=0.003. Thus, assigning to triple-positive CD4+T cells a cut-off <0.182%, TB-infected individuals could be classified as active TB subjects (0.182%). The magnitude of CD8+T-cell responses showed no differences between active TB and LTBI. Multifunctional CD4+T-cell responses could have the potential to identify at single time point subjects without TB infection and patients having active or latent TB.


  • Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4+ T cells

    by Ilaria Sauzullo, Fabio Mengoni, Claudia Mascia, Raffaella Rossi, Miriam Lichtner, Vincenzo Vullo, Claudio M. Mastroianni

    To ascertain whether multiparametric flow cytometry assessment of multifunctional Mycobacterium tuberculosis (Mtb)-specific CD4+ and CD8+ T cells can distinguish between untreated and treated patients with latent tuberculosis infection (LTBI), we enrolled 14 LTBI subjects treated with isoniazid (INH) therapy, 16 untreated LTBI patients, and 25 healthy controls. The analysis of mono-functional CD4+ and CD8+ T cells producing single cytokines showed significant differences only between uninfected and infected LTBI subjects (both treated and untreated). Conversely, the analysis of multifunctional CD4+ T cells revealed a significant reduction in the frequency of two CD4+ T cells subsets, those producing IFN-γ, IL-2, and TNF-α simultaneously (triple positive; p = 0.005) and those producing IL-2 alone (p = 0.0359), as well as a shift towards T cells producing only one cytokine in treated as compared to untreated LTBI subjects. Assigning a triple-positive CD4+ T cells a cut-off >0.082 %, 94 % of untreated LTBI patients were scored as positive, as compared to only 28 % of treated LTBI patients and none of the healthy controls. No significant differences between untreated and treated LTBI subjects in terms of Mtb-specific CD8+ T cell cytokine profiles (p > 0.05) were identified. The significant changes in the cytokine profiles of Mtb-specific T cells after INH therapy suggest that analysis of multifunctional T cells may be a promising means for the monitoring of LTBI treatment success.


  • Detecting latent tuberculosis in compromised patients

    by Ilaria Sauzullo, Vincenzo Vullo, Claudio M. Mastroianni

    The detection of latent tuberculosis infection (LTBI) in different categories of compromised patients is reviewed with focus on the role of strategies incorporating immunodiagnostic tests and analysis of epidemiological and clinical risk factors.The development of active tuberculosis (TB) is increased in compromised patients and is closely related to determinants for disease reactivation or newly acquired TB infection. A targeted detection of LTBI in these high-risk groups should be performed especially if preventive treatment is planned. The performance of immunodiagnostic tests is highly variable among different groups of immunocompromised individuals. Findings of cross-sectional studies indicate a better diagnostic accuracy of interferon-γ release assays over the tuberculin skin test. The critical issue is that in low-incidence countries, the positive and negative predictive values of any of immunodiagnostic tests were very poor. A targeted testing process involving analysis of TB risk factors increases the predictive positive values of immunodiagnostic tests and may improve LTBI detection.The LTBI detection in immunocompromised patients is a challenge. The development of new immunological biomarkers and integrated clinical and epidemiological strategies are needed to identify LTBI in compromised individuals and to plan preventive chemotherapies in those at risk of developing active TB.


  • Long-term IFN-γ and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results

    by Ilaria Sauzullo, Claudio M. Mastroianni, Fabio Mengoni, Angela Ermocida, Claudia Mascia, Alessandra Salotti, Mario Falciano, Vincenzo Vullo


  • The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature

    by Rossana Scrivo, Ilaria Sauzullo, Fabio Mengoni, Valeria Riccieri, Alfonso Maria Altieri, Laura Cantoro, Vincenzo Vullo, Claudio Maria Mastroianni, Guido Valesini

    Conversions and reversions of interferon-gamma (IFN-γ) release assays (IGRAs) were observed when these tests were repeated over time in the same individuals, including those treated with biological agents. In most studies, the variability of IFN-γ plasma levels was not paralleled by clinical change, but a few exceptions exist, in which IGRA conversion predicted the emergence of active tuberculosis (TB). We report the case of a Peruvian patient with rheumatoid arthritis (RA) and Crohn’s disease scheduled for treatment with adalimumab. TB screening demonstrated latent TB infection (LTBI), and the patient was started on isoniazid (INH) for 9 months. Adalimumab was initiated after 1 month since INH. QuantiFERON-TB Gold In-Tube, one of the IGRAs currently available, was serially repeated to monitor the status of TB infection during treatment with the biological agent. The patient developed active TB preceded by progressively rising levels of released IFN-γ. We came to know that she had withdrawn INH after 2 months on her own initiative. Considering the low rate of INH completion, serial IGRAs may help in the clinical vigilance during prophylaxis as well as anti-TNF treatment, at least in patients presenting other risk factors aside from the state of immunosuppression.


  • Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists

    by I Sauzullo, R Scrivo, F Mengoni, A Ermocida, M Coppola, G Valesini, V Vullo, C M Mastroianni

    Summary: Although monitoring tuberculosis (TB) infection during long-term treatment with tumour necrosis factor (TNF) antagonists is of great importance, no monitoring strategy has yet proved successful. Indeed, even the newly proposed interferon-gamma release assays (IGRAs) are known to produce dynamic changes in IFN-γ plasma levels, making them unreliable indicators of patients' pathological/clinical status. We used intracellular cytokine flow cytometry (ICCFC) to investigate the performance of multi-functional CD4+ T cells producing IFN-γ, interleukin (IL)-2 and/or TNF in response to Mycobacterium tuberculosis-specific antigens in subjects treated with TNF antagonists. Patients were classified into three groups based on their TB status before commencement of treatment and on IFN-γ level fluctuations evaluated by IGRA during a 36-month follow-up period. The cytokine profile of M. tuberculosis-specific CD4+ T cells showed that latent tuberculosis infection (LTBI) subjects had a higher frequency of double-positive IFN-γ+ IL-2+ CD4+ T cells and triple-positive IFN-γ+ IL-2+ TNF+ CD4+ T cells compared to those without LTBI, who showed IFN-γ-level fluctuations over time. In contrast, this latter group of patients showed similar proportions of cells producing IFN-γ alone, IL-2 alone and IL-2 in combination with TNF in response to M. tuberculosis-specific antigens. It therefore appears that patients with and without LTBI infection are characterized by different intracellular cytokine profiles. This is the first study evaluating ICCFC in patients treated with TNF antagonists, and suggests that multi-functional analysis of CD4+ T cells could be useful for ruling out TB infection in patients classified at screening as LTBI-negative but who show IGRA fluctuations under long-term TNF antagonist treatment.


    • 1 April 2014
      • Vol. 37  (2) , 153-61

    Interferon-γ release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response.

    by Ilaria Sauzullo, Fabio Mengoni, Angela Ermocida, Anna P Massetti, Claudia D'Agostino, Gianluca Russo, Alessandra Salotti, Mario Falciano, Vincenzo Vullo, Claudio M Mastroianni

    The objective of the study was to: 1) investigate the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) in HIV-infected patients with active tuberculosis (TB); 2) evaluate the sequential changes in QFT-GIT assay during the treatment response; 3) investigate the direct in vitro effects of antituberculous drugs on both secretion of IFN-g and apoptosis of T cells. Forty-four HIV-patients with active TB were enrolled and tested with QFT-GIT. Thirteen of them were followed longitudinally by QFT-GIT, performed at baseline and six and nine months after TB-treatment onset. For in vitro experiments, cells from healthy donors and HIV-naive subjects were pretreated with four antituberculous-drugs, and then examined for IFN-g secretion and apoptosis of T-cells. The QFT-GIT was positive in 66%, negative in 11.3% and indeterminate in 22.7%. Longitudinal analysis in 13 HIV-TB subjects showed that at therapy completion a reversion to negative response was found only in 38.4% of patients, but in 30.7% the QFT-GIT remained positive. Overall, during the anti-TB treatment no significant decrease in average IFN-g response was observed in these patients (p<0.001). In vitro experiments showed that the four antituberculous- drugs, within the range of therapeutically achievable concentrations, did not exert any down-regulatory effect on IFN-g production and did not have any effect on apoptosis of T cells from HIV naïve subjects. Despite the high rate of indeterminate results, QFT-GIT assay may represent a good tool in the diagnostic workup for active TB in HIV-patients. Although the antituberculous drugs do not have any direct effect on host immune response to mycobacterial antigen, changes in longitudinal IGRA response have been found during in vivo anti-TB treatment.